Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response

被引:335
作者
Lind, T
Havelund, T
Carlsson, R
AnkerHansen, O
Glise, H
Hernqvist, H
Junghard, O
Lauritsen, K
Lundell, L
Pedersen, SA
Stubberod, A
机构
[1] KARNSJUKHUSET, DEPT SURG, SKOVDE, SWEDEN
[2] SAHLGRENS UNIV HOSP, DEPT SURG, S-41345 GOTHENBURG, SWEDEN
[3] NAL, DEPT SURG, TROLLHATTAN, SWEDEN
[4] MOTALA HOSP, DEPT SURG, MOTALA, SWEDEN
[5] ASTRA HASSLE AB, MOLNDAL, SWEDEN
[6] VARNAMO HOSP, DEPT SURG, VARNAMO, SWEDEN
[7] ODENSE UNIV HOSP, DEPT MED, DK-5000 ODENSE, DENMARK
[8] ODENSE UNIV HOSP, DEPT SURG, DK-5000 ODENSE, DENMARK
关键词
endoscopy-negative; gastro-oesophageal reflux; heartburn; omeprazole; placebo; pH monitoring;
D O I
10.3109/00365529709011212
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Data an limited on the value of effective antisecretory therapy in the relief of heartburn in patients without oesophagitis. Methods: Patients with heartburn, without endoscopic signs of oesophagitis, were randomized to double-blind treatment with omeprazole, 20 or 10 mg once daily, or placebo, for 4 weeks (n=509). Pre-treatment oesophageal acid exposure was assessed using 24-h intra-oesophageal pH monitoring. Heartburn was assessed at 2 and 4 weeks. Results: At 4 weeks the proportion of patients with complete absence of heartburn was 46% (95% confidence interval, 39-53%) with 20 mg omeprazole, 31% (25-38%) with 10 mg omeprazole, and 13% (7-20%) with placebo. Satisfaction with therapy was reported by 66%, 57%, and 31% of the patients, respectively. Conclusions: Omeprazole, 20 and 10 mg once daily, provides rapid relief of heartburn in patients without endoscopic oesophagitis.
引用
收藏
页码:974 / 979
页数:6
相关论文
共 29 条
[21]   3 YEAR FOLLOW-UP OF PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE [J].
SCHINDLBECK, NE ;
KLAUSER, AG ;
BERGHAMMER, G ;
LONDONG, W ;
MULLERLISSNER, SA .
GUT, 1992, 33 (08) :1016-1019
[22]   REFLUX RELATED SYMPTOMS IN PATIENTS WITH NORMAL ESOPHAGEAL EXPOSURE TO ACID [J].
SHI, G ;
DESVARANNES, SB ;
SCARPIGNATO, C ;
LERHUN, M ;
GALMICHE, JP .
GUT, 1995, 37 (04) :457-464
[23]   2 DOSES OF OMEPRAZOLE VERSUS PLACEBO IN SYMPTOMATIC EROSIVE ESOPHAGITIS - THE UNITED-STATES MULTICENTER STUDY [J].
SONTAG, SJ ;
HIRSCHOWITZ, BI ;
HOLT, S ;
ROBINSON, MG ;
BEHAR, J ;
BERENSON, MM ;
MCCULLOUGH, A ;
IPPOLITI, AF ;
RICHTER, JE ;
AHTARIDIS, G ;
MCCALLUM, RW ;
PAMBIANCO, DJ ;
VLAHCEVIC, RZ ;
JOHNSON, DA ;
COLLEN, MJ ;
LYON, DT ;
HUMPHRIES, TJ ;
CAGLIOLA, A ;
BERMAN, RS .
GASTROENTEROLOGY, 1992, 102 (01) :109-118
[24]   EPIDEMIOLOGY AND NATURAL-HISTORY OF GASTROESOPHAGEAL REFLUX DISEASE [J].
SPECHLER, SJ .
DIGESTION, 1992, 51 :24-29
[25]   LOWERED ESOPHAGEAL SENSORY THRESHOLDS IN PATIENTS WITH SYMPTOMATIC BUT NOT EXCESS GASTROESOPHAGEAL REFLUX - EVIDENCE FOR A SPECTRUM OF VISCERAL SENSITIVITY IN GORD [J].
TRIMBLE, KC ;
PRYDE, A ;
HEADING, RC .
GUT, 1995, 37 (01) :7-12
[26]   OMEPRAZOLE (40 MG) IS SUPERIOR TO RANITIDINE IN SHORT-TERM TREATMENT OF ULCERATIVE REFLUX ESOPHAGITIS [J].
VANTRAPPEN, G ;
RUTGEERTS, L ;
SCHURMANS, P ;
COENEGRACHTS, JL .
DIGESTIVE DISEASES AND SCIENCES, 1988, 33 (05) :523-529
[27]   EPIDEMIOLOGY OF REFLUX DISEASE AND REFLUX ESOPHAGITIS [J].
WIENBECK, M ;
BARNERT, J .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :7-13
[28]  
WIENER GJ, 1988, AM J GASTROENTEROL, V83, P358
[29]  
ZEITOUN P, 1989, GASTROEN CLIN BIOL, V13, P457